GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) Director Casdin Capital, Llc purchased 140,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $43.81 per share, for a total transaction of $6,133,400.00. Following the transaction, the director owned 3,507,164 shares of the company’s stock, valued at $153,648,854.84. This trade represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Casdin Capital, Llc also recently made the following trade(s):
- On Tuesday, May 19th, Casdin Capital, Llc purchased 185,000 shares of GeneDx stock. The shares were purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00.
- On Monday, May 18th, Casdin Capital, Llc purchased 175,000 shares of GeneDx stock. The shares were purchased at an average cost of $42.55 per share, for a total transaction of $7,446,250.00.
GeneDx Trading Down 0.0%
WGS opened at $47.31 on Friday. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -17.65 and a beta of 2.06. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87. The business’s 50 day moving average is $59.72 and its two-hundred day moving average is $98.90. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.
Institutional Trading of GeneDx
A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of GeneDx by 77.5% in the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock valued at $15,066,000 after buying an additional 102,456 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of GeneDx by 31.2% in the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after buying an additional 5,951 shares in the last quarter. Ashford Capital Management Inc. boosted its stake in shares of GeneDx by 31.9% in the first quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after buying an additional 42,186 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of GeneDx by 99.2% in the first quarter. Quantinno Capital Management LP now owns 3,810 shares of the company’s stock valued at $245,000 after buying an additional 1,897 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in shares of GeneDx in the first quarter valued at approximately $15,601,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
WGS has been the topic of several research analyst reports. Canaccord Genuity Group set a $75.00 price target on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Guggenheim dropped their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Craig Hallum reissued a “buy” rating and issued a $85.00 target price on shares of GeneDx in a report on Tuesday, May 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.43.
Read Our Latest Stock Report on WGS
GeneDx Company Profile
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
